Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex ...

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...

In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...

A quote shared during our bi-weekly Tuesday multiple myeloma support group, where five or more gather in the virtual Zoom ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson ...

Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can ...

Novel therapies for certain autoimmune diseases have been developed to end B cell-driven immune attacks on normal tissues.

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

Binod Dhakal, MD, associate professor of medicine in the Division of Hematology at the Medical College of Wisconsin, ...

Oncopeptides AB ( ($SE:ONCO) ) has issued an update. Oncopeptides AB announced the publication of three case reports in the Journal of Cancer ...